MDWD vs USNA
MediWound Ltd. and Usana Health Sciences Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MDWD | USNA |
|---|---|---|
| Revenue | $17.0M | $925.3M |
| Net income | $-23.9M | $10.8M |
| Gross margin | 19.2% | 78.3% |
| Net margin | −140.8% | 1.2% |
| Return on equity | −63.9% | 2.0% |
| Diluted EPS | −$2.10 | $0.58 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-21.6M | $8.5M |
| Equity | · | $533.1M |
| Net debt / equity | · | · |
| Current ratio | 2.33× | 2.24× |
| Revenue CAGR 5y | −4.9% | −4.0% |
| Profit CAGR 5y | · | −38.7% |
USNA bills 54.6× the revenue of MDWD, and MDWD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MDWD | USNA |
|---|---|---|
| FY2025 | $17.0M | $925.3M |
| FY2024 | $20.2M | $854.5M |
| FY2023 | $18.7M | $921.0M |
| FY2022 | $26.5M | $998.6M |
| FY2021 | $23.8M | $1.2B |
| FY2020 | $21.8M | $1.1B |
| FY2019 | $31.8M | $1.1B |
| FY2018 | $3.4M | $1.2B |
| FY2017 | $2.5M | $1.0B |
| FY2016 | $1.6M | $1.0B |
Bottom line
| Fiscal year | MDWD | USNA |
|---|---|---|
| FY2025 | $-23.9M | $10.8M |
| FY2024 | $-30.2M | $42.0M |
| FY2023 | $-6.7M | $63.8M |
| FY2022 | $-19.6M | $69.3M |
| FY2021 | $-13.6M | $116.5M |
| FY2020 | $-9.2M | $124.7M |
| FY2019 | $5.0M | $100.5M |
| FY2018 | $-1.1M | $126.2M |
| FY2017 | $-22.1M | $62.5M |
| FY2016 | $-18.9M | $100.0M |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$908,298,000 | USNA |
| FY2024 | −$834,281,000 | USNA |
| FY2023 | −$902,324,000 | USNA |
| FY2022 | −$972,105,000 | USNA |
| FY2021 | −$1,162,701,000 | USNA |
| FY2020 | −$1,112,881,000 | USNA |
| FY2019 | −$1,029,113,000 | USNA |
| FY2018 | −$1,185,847,000 | USNA |
| FY2017 | −$1,044,769,000 | USNA |
| FY2016 | −$1,004,525,000 | USNA |
| FY2015 | −$917,898,000 | USNA |
USNA has reported the higher revenue in every one of these 11 fiscal years. The gap has narrowed since the earliest year compared.
11 of 17 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −142.0 pp | USNA |
| FY2024 | −154.4 pp | USNA |
| FY2023 | −42.9 pp | USNA |
| FY2022 | −80.9 pp | USNA |
| FY2021 | −66.8 pp | USNA |
| FY2020 | −53.2 pp | USNA |
| FY2019 | +6.1 pp | MDWD |
| FY2018 | −41.7 pp | USNA |
| FY2017 | −893.4 pp | USNA |
| FY2016 | −1222.1 pp | USNA |
The higher net margin has changed hands between MDWD and USNA over this period.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MDWD's net margin has been more volatile than USNA's over the 10 comparable fiscal years — 403.5 percentage points of standard deviation against 2.9.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MDWD and USNA over these 10 fiscal years — MDWD led in 1 and USNA in 9.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MDWD's return on equity has been more volatile than USNA's over the 9 comparable fiscal years — 78.8 percentage points of standard deviation against 11.9.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MDWD and USNA over these 9 fiscal years — MDWD led in 1 and USNA in 8.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.